Enter multiple symbols separated by commas



  • Ranbaxy filed "grossly inadequate" applications seeking approval for its drugs and deceived the FDA into granting approvals and giving the company market exclusivity, the class action lawsuit asserts. The FDA has banned import of drugs from all of Ranbaxy's India- based plants under a wider scrutiny of the country's $15 billion pharmaceutical industry,...

  • Jim O’Neill thinks we need $2B to fund new drugs Thursday, 14 May 2015 | 11:13 AM ET

    As the list of drug-resistant bacteria grows, more research into new antibiotics is needed, according to ex-Goldman Sachs economist Jim O’Neill, who was also made U.K. Commercial Secretary on Thursday.

  • ASCO's immunotherapies update   Thursday, 14 May 2015 | 6:19 AM ET
    ASCO's immunotherapies update

    CNBC's Meg Tirrell takes a look at new cancer-fighting drugs and other therapies in the pipeline.

  • LONDON, May 14- Companies that develop new antibiotics should be awarded prize money of up to $3.5 billion for each new drug, instead of selling the medication at a profit, a review backed by Britain's government said on Thursday. The review, lead by former Goldman Sachs chief economist Jim O'Neill, said the lump sum payments could add up to $16- $37 billion over 10...

  • Biotech to watch ahead of ASCO   Wednesday, 13 May 2015 | 2:36 PM ET
    Biotech to watch ahead of ASCO

    The American Society of Clinical Oncology conference will occur at the end of May in Chicago. CNBC's Meg Tirrell reports which companies investors should watch. Also, Les Funtleyder, ESquared Asset Management, shares his view.

  • How much do Americans spend on drugs?   Wednesday, 13 May 2015 | 1:52 PM ET
    How much do Americans spend on drugs?

    A new report says the number of Americans being billed more than $100,000 a year for their prescriptions has tripled in the past year. CNBC's Meg Tirrell breaks down the report, saying slightly more than half of the spenders were men.

  • Drug 'super spenders' rack up $52 billion last year   Wednesday, 13 May 2015 | 9:00 AM ET
    Drug 'super spenders' rack up $52 billion last year

    The number of Americans spending more than $100,000 on medicine nearly tripled in 2014 compared to the prior year.

  • Your prescriptions costs what?   Wednesday, 13 May 2015 | 6:44 AM ET
    Your prescriptions costs what?

    CNBC's Meg Tirrell takes a look at the soaring prices of some drugs and what is driving costs higher.

  • --Amgen in late 2012 bought Decode Genetics for $415 million in cash to gain access to a database of complete genetic sequences of 2,636 Icelanders. --In January 2014, Regeneron Pharmaceuticals Inc signed a deal with Geisinger Health System in Pennsylvania to sequence DNA from as many as 250,000 volunteers from Geisinger's pool of 3 million patients.

  • Regeneron Pharmaceuticals Inc, which signed a deal with Pennsylvania's Geisinger Health System in January 2014 to sequence partial genomes of some 250,000 volunteers, is already claiming discoveries based on the new approach. Pfizer Inc, Roche Holding AG and Biogen Inc are working on similar projects that use DNA and patient health data to find new drug...

  • Moderna Therapeutics No. 1 on Disruptor 50: Here's why

    Moderna Therapeutics' CEO Stephane Bancel discusses the company's discovery of utilizing messenger RNA, which helps to direct the body's own cells to build proteins and fight rare diseases.

  • Disruptor 50: No.1 Moderna Therapeutics Tuesday, 12 May 2015 | 7:00 AM ET
    Stéphane Bancel, president and founding CEO, Moderna Therapeutics

    A biotech company that helps the human body make the medicine it needs to cure a range of disease—from cancer to diabetes.

  • Disruptor 50: No. 29 Intarcia Therapeutics Tuesday, 12 May 2015 | 7:00 AM ET
    Kurt Graves, CEO of Intarcia Therapeutics

    Investors believe Intarcia's drug-delivery system could very well upend the $55 billion worldwide market for treating Type-2 diabetes.

  • A hot biotech that may be the next Genentech Tuesday, 12 May 2015 | 7:00 AM ET

    This company has raised $1 billion to develop the Holy Grail in drugs: Have the body's own cells churn out proteins to fight disease.

  • *Actavis initial forecast historically conservative- analysts. Sales of Allergan products for 15 days and the drugs acquired with the Forest Laboratories deal helped Actavis beat revenue estimate in the quarter ended March 31. Actavis, whose shares were up 3 percent, outbid Canadian drugmaker Valeant Pharmaceuticals International Inc and activist...

  • Actavis beats earnings estimates   Monday, 11 May 2015 | 8:30 AM ET
    Actavis beats earnings estimates

    Actavis beats earnings estimates again, making it nine out of the last ten quarters.

  • May 11- Drugmaker Actavis Plc, which completed its $66 billion acquisition of Botox maker Allergan in March, reported a better-than-expected quarterly profit, helped by higher sales of its branded drugs in North America. Actavis forecast 2015 revenue of $20.5 billion to $21 billion on Monday. Actavis said first-quarter results included business from...

  • Actavis revenue jumps 60 pct Monday, 11 May 2015 | 6:45 AM ET

    May 11- Drugmaker Actavis Plc's quarterly revenue jumped almost 60 percent, helped by higher sales of its branded drugs in North America, but charges related to its acquisition of Botox maker Allergan Inc pushed the company into a net loss. The company reported a net loss of $535.2 million, or $1.85 per share, attributable to shareholders, in the first quarter...

  • The company has been steadfast in its refusal to combine with Teva and is instead encouraging shareholders to support its own $34 billion unsolicited offer for over-the-counter drugmaker Perrigo Co Plc. Teva said on Tuesday it will move ahead with its plans to acquire Mylan if the Perrigo deal is not completed. Speaking privately to investors this week,...

  • New drug to boost women's libido   Friday, 8 May 2015 | 10:30 AM ET
    New drug to boost women's libido

    The Food and Drug Administration will have outside medical experts evaluate a much debated drug designed to boost sexual desire in women.